Sign in
Taking peoplePhase 3

Dalteparin to prevent blood clots in people with severe traumatic brain injury

Tests dalteparin against saline for preventing blood clots in adults with traumatic brain injury.

Key facts

Who runs it
Sunnybrook Health Sciences Centre
Where
Canada12 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury (PROTEST)
Status
Recruiting
Phase
Phase 3
People taking part
1,100 people, planned
Started
19 Jul 2018
Expected to end
Dec 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Dalteparin
  • Saline
Record updated
19 September 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a severe or moderate traumatic brain injury (head injury). It tests whether Dalteparin, a blood thinner, prevents blood clots compared with saline.

Age
18 years and older
Sex
All sexes
Disease stage
Severe TBI with a GCS (coma score) of ≤8. Or moderate TBI with GCS 9-12, in intensive care, with bleeding in the brain on the first CT scan. Moderate cases also need a breathing machine at screening, or more bleeding on a repeat CT scan.
Earlier treatment
The first dose of study drug must be possible within the first 3 calendar days after the injury.

Main reasons for not taking part

  • Known allergy to FRAGMIN (Dalteparin), other heparins, benzyl alcohol or pork products
  • Past heparin-induced low platelet count, or uncontrollable active bleeding or major clotting disorders
  • Severe uncontrolled high blood pressure (BP>210 despite medications)
  • Known pregnancy
  • Weight under 45 kg (99 lb) or over 120kg (265 lb (120 kg)), or not expected to survive more than 48 hours from admission

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • The pragmatic nature of this study seeks to include all consecutive patients presenting with significant TBI, regardless of whether ICB is evident at presentation. Inclusion criteria are the following:
  • Patients with severe TBI defined as GCS of ≤8, or
  • Patients with moderate TBI defined as GCS = 9-12, admitted to ICU, with at least some ICB present on initial CT scan and any of the following:
  • Requiring invasive mechanical ventilation at the time of screening
  • Increased ICB on repeat CT scan compared to initial CT scan
  • Upon randomization the patient will be able to receive the first dose of study drug in the first 3 calendar days from the time of injury
  • ≥ 18 years of age

Who cannot take part

  • Known Hypersensitivity to FRAGMIN (Dalteparin), or its constituents including benzyl alcohol or to other low molecular weight heparins and/or heparins or pork products
  • Uncontrollable active bleeding
  • Known major blood clotting disorders
  • Known acute gastroduodenal ulcer (with active bleeding)
  • Severe uncontrolled hypertension (i.e. BP>210 despite medications)
  • Presence of another confounding factor that can adequately explain the poor GCS at time of presentation (e.g. drug toxicity, seizure)
  • Known history of confirmed or suspected immunologically-mediated heparin-induced thrombocytopenia (delayed-onset severe thrombocytopenia), and/or in patients with a known history of a positive in vitro platelet-aggregation test in the presence of FRAGMIN (Dalteparin) is positive
  • All participants meeting any of the following exclusion criteria at baseline will be excluded from participation in this study:
  • Known septic endocarditis
  • Known diabetic or hemorrhagic retinopathy
  • Anticipated to be unable to receive SCD on at least one lower extremity due to nature of injuries for duration of intervention period
  • Known presence of irreversible coagulopathies
  • Known Pregnancy
  • Participants extremely low weight (<45 kg), or extremely high weight (>120kg)
  • Not expected to survive more than 48 hours from admission

This trial is currently available in Canada.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a phase III, multi-centre, double blind, randomized controlled trial of patients with traumatic brain injury (TBI).

The 2 groups in the trial

  • AnticoagulantExisting treatment, for comparison

    Dalteparin sodium (at a dose of 5000 IU once daily by subcutaneous injection) for 7 days upon randomization after hospital admission.

    Treatment: Dalteparin

  • SalinePlacebo, for comparison

    Saline (0.2 mL) once daily by subcutaneous injection for 7 days upon randomization after hospital admission.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
PROTEST Trial - PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury, a Double-blind Randomized Controlled Trial
Plain-language title
Dalteparin to prevent blood clots in people with severe traumatic brain injuryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Publications
Record updated
19 September 2024